 Grifols Therapeutics Inc. conducted a multi-center, randomized, double-blind, crossover study to evaluate the safety, immunogenicity, and pharmacokinetics PK of Liquid Alpha1-PI compared to the currently licensed product, Prolastin-C, in subjects with Alpha1-Antitrypsin Deficiency AATD. 